Articles On Orthocell (ASX:OCC)

John Van Der Wielen succeeds Neale Fong and adds to his chairmanships of the ASX-listed biotech Orthocell and the WA Government’s Future Health and Research Fund. 

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Host Tylah Tully chats with Orthocell (ASX:OCC) managing director and CEO Paul Anderson about the growing momentum behind Remplir, as surgeons find  a new indication for the company’s lead product. Most recently, the device has been adopted...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Company to invest in further research to strengthen clinical evidence ahead of mediu...

Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from...

Orthocell (ASX:OCC) has seen its share price jump on Thursday as the company unveils its latest early-stage successes observed in Australian prostate surgery patients who use nerve repair product Remplir. Listen to the HotCopper podcast...

Orthocell Ltd (ASX: OCC) shares are catching the eye on Thursday morning. At the time of writing, the ASX All Ords stock is up 7.5% to $1.08. Why is this ASX All Ords stock jumping? Investors have been buying the regenerative medicine compa...

Highlights Broad uptrend momentum seen across diverse sectors. Multiple companies experience renewed chart strength. Downtrend signals highlight shifting market sentiment. A comprehensive exploration of rising and weak...

Australian biotechs are carving out expanded territory in the US Truscreen edges towards cash flow break even CSL is extracting more blood from donors, more efficiently   Today’s crop of ASX announcements highlights the potential of the U...

ASX recovers from session lows of -0.91pc to fall -0.13pc Info tech, commodities weakness undercut market Banks, defensive sectors mount resistance ASX battens down the hatches It was looking like we were in for another 90-point routing...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Investors are stumping up cash for life sciences capital raisings – but the stories need to be well presented After an “incredibly tumultuous” nine months, fundraisings are on track to meet last year’s bumper tally of $2.9 billion Two medt...

ASX bounces off lows of -0.59pc to gain 0.15pc Info tech, banking stocks lead gains US-China trade truce undercuts critical mineral stocks   Westpac fuels banking wins The ASX 200 was set to notch a fifth day of losses before staging a la...

Poor Chinese relations, Covid, war and US tariffs prove too much for device maker Uscom The Mayne Health takeover deal isn’t over, but the prognosis is dire Bioxyne strikes medical cannabis vape import deal   Uscom bows out Uscom (ASX:UCM...

Big returns could be on the cards for buyers of Syrah Resources Ltd (ASX: SYR) shares. That's the view analysts at Macquarie Group Ltd (ASX: MQG), which are feeling very bullish about the ASX mining stock. What is the broker saying about th...

ASX falls to two-week lows, down 0.96pc Healthcare, industrials, financials smashed by high inflation read Uranium and resource stocks stage recovery   ASX tumbles on CPI read but uranium rallies Any chance of an intraday recovery was put...

Highlights Materials sector shows resilience in midday session Healthcare segment under performance pressure Key updates from Almonty Industries and Orthocell Materials stocks outperformed in midday trade a...

Orthocell appoints exclusive in-country distributor for flagship nerve-repair product Remplir in Hong Kong MontsMed is a highly credentialled medical device distribution company in Hong Kong First surgical cases and sales in Hong Kong expe...

Good Afternoon and welcome to HotCopper‘s Market Close, I’m Jon Davidson. It was a strong start to the week at least, ahead of Anthony Albanese and Trump’s meeting in Washington taking place tonight and in the early hours of Tuesday, as the...

Orthocell to increase its stake in fellow WA biotech Marine Biomedical from 1.7% to 12% through a $1 million investment A pivotal study on Marine’s Biomedical’s flagship product PearlBone nears completion to support US FDA approval Invest...

Orthocell (ASX:OCC) has boosted its stake in a Western Australia-based biotech company called ‘PearlBone,’ which uses nacre, the material from which pearls are made, but which also includes part of the shell, to create bone regeneration pro...

Botanix shares leap 17% on a solid start to the US rollout of the company’s anti-sweating treatment, Sofdra Radiopharm raises up to $40 million, while Orthocell banks $30 million Avita faces tough questions after surprise CEO departure B...

ASX falls 73 points, sliding back below 9000 points Only three sectors marginally higher, XGD up 1.27pc Defence-related, energy and info tech stocks tumble   The ASX 200 couldn’t maintain much of its gains this week, giving up the fight j...

Let’s dive into what HotCopper users have been tracking on Friday in what has been a fairly jarring day for many – but perhaps not for those who took profits on Thursday. Listen to the HotCopper podcast for in-depth discussions and insi...

The ASX health sector moved up 1.30% for the week, while the broader market inched up 0.12% Aroa recorded fourth consecutive quarter of positive net cash flow with Myriad breaking records Orthocell raised $30 million in oversubscribed plac...

Orthocell Ltd (ASX: OCC) shares are on course to end the week in the red. In morning trade, the ASX stock is down 7% to $1.33. However, longer term shareholders won't be too downbeat. That's because the regenerative medicine company's share...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Another volatile session on Wall Street, as US/China trade concerns lingered, but th...

ASX closes up 1.03% to four-day high with strong performances in healthcare, materials and financials Gold hits another all-time high – of US$4211 per ounce Telix surges 16% after reporting robust September quarter revenue from its prostat...

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front of those trends is so important for any trader worth their salt. Listen to the Ho...

The funds will also support the purchase of a 15 per cent stake in fellow WA biotech, the unlisted Marine Biomedical, and a clinical study into the use of Remplir in prostate cancer surgery.

Netwealth Group Ltd (ASX: NWL) shares tumbled 4% yesterday, finishing Monday's trading at $31.21.  Despite the drop, Netwealth shares remain up almost 14% over the last year.  Netwealth is a financial services and technology company....

With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading...

The S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a disappointing decline. At the time of writing, the benchmark index is down 0.7% to 8,898.4 points. Four ASX shares that are not letting that hold them back are lis...

The Australian share market has traditionally delivered a return of approximately 10% per annum. But investors may not have to settle for that when analysts at Morgans are expecting even greater returns for the ASX 200 shares named below. L...

Regenerative medicine is a fast-growing healthcare field that harnesses the body’s natural healing ability At Monash University, the Australian Regenerative Medicine Institute is internationally recognised for pioneering research Several A...

ASX 200 closes 0.13% lower on Friday, despite eight of 11 sectors higher  Tech sector leads gains while resource stocks weigh heavily Trigg Minerals continues to progress its proposed US Nasdaq listing    The ASX 200 ended the week lower...

Now could be a good time to pounce on the ASX 200 stock in this article. That's the view of analysts at Bell Potter, which believe that market-beating returns could be on the cards for investors over the next 12 months. Which ASX 200 stock?...

It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up a fraction to 8,971.3 points. Four ASX shares that are rising more than most today are listed b...

Very few investors had heard of Dateline Resources Ltd (ASX: DTR) at the start of the year. In early January, shares in this ASX mining stock were changing hands at $0.003 per share, with its market capitalisation clocking in at less th...

ASX gold shares are having an incredible run in 2025 amid the gold price soaring above US$4,000 per ounce for the first time overnight. At the time of writing, the gold price is US$4,011 per ounce, representing an astonishing 53% gain i...

Local tech titans are being given a platform for their achievements at the upcoming EY Entrepreneur Of The Year™ awards on October 15. The founders of Employment Hero, Tiimely, Pay.com.au and Orthocell will go head to head in the Technology...

The S&P/ASX 200 Index (ASX: XJO) is climbing higher today, up 1.27% at the time of writing. For the year, it is 9.27% higher. It's decent growth for the past 12-month period, but there is one stock that has far outpaced the index and...

  Orthocell achieves record revenue of $3 million for Q1 FY26, up 9.1% on previous record in Q4 FY25 Revenue driven primarily by increasing market penetration of flagship nerve repair product Remplir in existing markets Sixth consecutive q...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1% to 8,935.9 points. Four ASX shares that have failed to follow the market higher today are l...

The S&P/ASX 200 Index (ASX: XJO) is back on form and racing higher on Thursday. In afternoon trade, the benchmark index is up 1.05% to 8,939.4 points. Four ASX shares that are rising more than most today are listed below. Here's why t...

Impedimed and Avita Medical have won a ‘pay rise’ from private and public US payors Orthocell posts record revenue – an entrée perhaps, with US sales main course to come  Gut disorders house Immuron outlines a packed October schedule   Fe...

Superannuation fund research house Chantwest has teamed up with retirement educator Bec Wilson on a new rating – the Epic Retirement Tick – and the bad news is only six out of Australia's more than 60 super funds have made the grade....

The All Ordinaries Index (ASX: XAO) is up 0.6% today, with ASX All Ords stock Orthocell Ltd (ASX: OCC) leaping ahead of those gains. Shares in the regenerative medicine company closed yesterday trading for $1.435. In early morning trade on...

At the time of writing, there are roughly 380 ASX ETFs for investors to choose from.  However, in recent years, there has been more and more with more specific themes like AI, tech, or sustainability. Other times, new ETFs come...